Close Menu

NEW YORK – A public-private partnership in Oklahoma is gearing up to begin high-throughput molecular diagnostic testing for COVID-19 using Fluidigm's microfluidic technology, the partners said on Thursday.

The real-time PCR test, developed by the nonprofit Oklahoma Medical Research Foundation and the University of Oklahoma Health Sciences Center, will run on Fluidigm's Biomark HD system and is intended for large-scale testing of patients across the OU Medicine healthcare system and, eventually, the entire state, stakeholders said in a webcast announcing the initiative on Thursday.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Mar
31
Sponsored by
MilliporeSigma

This webinar will outline the development and commercialization journey of a novel CRISPR-based SARS-CoV-2 test. 

Apr
06
Sponsored by
Beckman Coulter

In this webinar session, Dr. David Harris and Dr. Ryan Sprissler, who led the student and employee testing program at University of Arizona, will discuss how the university has remained physically open with nearly 25 percent of its population on campus, while keeping infection rates below 2 percent.